Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells - PubMed (original) (raw)

. 2000 Mar 24;269(3):652-9.

doi: 10.1006/bbrc.2000.2343.

Affiliations

• PMID: 10720471
• DOI: 10.1006/bbrc.2000.2343

Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells

A V Somlyo et al. Biochem Biophys Res Commun. 2000.

Abstract

The Rho-kinase inhibitor, Y-27632, inhibited in vitro chemotactic migration to bone marrow fibroblast conditioned media and metastatic growth in immune-compromised mice of highly invasive human prostatic cancer (PC3) cells. Y-27632 also reduced myosin light chain phosphorylation and markedly altered the morphology of cells that developed numerous processes containing microtubules. A strikingly different, rounded phenotype was induced by an inhibitor of myosin light chain kinase, ML9. The M(110-130) subunit of the myosin phosphatase that is regulated by Rho-kinase was present in PC3 cells that contained significantly more RhoA than the less invasive, LNCaP cells. Y-27632 also inhibited angiogenesis as measured by endothelial cell tube formation on Matrigel. We conclude that invasiveness of human prostate cancer is facilitated by the Rho/Rho-kinase pathway, and exploration of selective Rho-kinase inhibitors for limiting invasive progress of prostate cancer is warranted.

Copyright 2000 Academic Press.

PubMed Disclaimer

Similar articles

• Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.
  Somlyo AV, Phelps C, Dipierro C, Eto M, Read P, Barrett M, Gibson JJ, Burnitz MC, Myers C, Somlyo AP. Somlyo AV, et al. FASEB J. 2003 Feb;17(2):223-34. doi: 10.1096/fj.02-0655com. FASEB J. 2003. PMID: 12554701
• Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork.
  Rosenthal R, Choritz L, Schlott S, Bechrakis NE, Jaroszewski J, Wiederholt M, Thieme H. Rosenthal R, et al. Exp Eye Res. 2005 Jun;80(6):837-45. doi: 10.1016/j.exer.2004.12.013. Exp Eye Res. 2005. PMID: 15939040
• Okadaic acid induces phosphorylation and translocation of myosin phosphatase target subunit 1 influencing myosin phosphorylation, stress fiber assembly and cell migration in HepG2 cells.
  Lontay B, Kiss A, Gergely P, Hartshorne DJ, Erdodi F. Lontay B, et al. Cell Signal. 2005 Oct;17(10):1265-75. doi: 10.1016/j.cellsig.2005.01.008. Epub 2005 Mar 3. Cell Signal. 2005. PMID: 16038801
• Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632.
  Rao PV, Deng PF, Kumar J, Epstein DL. Rao PV, et al. Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37. Invest Ophthalmol Vis Sci. 2001. PMID: 11274082
• Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors.
  Hopkins AM, Pineda AA, Winfree LM, Brown GT, Laukoetter MG, Nusrat A. Hopkins AM, et al. Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G806-17. doi: 10.1152/ajpgi.00333.2006. Epub 2006 Nov 30. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17138966

Cited by

• Excitable Rho dynamics control cell shape and motility by sequentially activating ERM proteins and actomyosin contractility.
  Marshall-Burghardt S, Migueles-Ramírez RA, Lin Q, El Baba N, Saada R, Umar M, Mavalwala K, Hayer A. Marshall-Burghardt S, et al. Sci Adv. 2024 Sep 6;10(36):eadn6858. doi: 10.1126/sciadv.adn6858. Epub 2024 Sep 6. Sci Adv. 2024. PMID: 39241071 Free PMC article.
• ROCK2-RNA interaction map reveals multiple biological mechanisms underlying tumor progression in renal cell carcinoma.
  Hong Z, Chen X, Wang L, Zhou X, He H, Zou G, Liu Q, Wang Y. Hong Z, et al. Hum Cell. 2023 Sep;36(5):1790-1803. doi: 10.1007/s13577-023-00947-x. Epub 2023 Jul 7. Hum Cell. 2023. PMID: 37418232
• Morphometric Analysis of Rat Prostate Development: Roles of MEK/ERK and Rho Signaling Pathways in Prostatic Morphogenesis.
  Hu WY, Afradiasbagharani P, Lu R, Liu L, Birch LA, Prins GS. Hu WY, et al. Biomolecules. 2021 Dec 4;11(12):1829. doi: 10.3390/biom11121829. Biomolecules. 2021. PMID: 34944473 Free PMC article.
• Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential.
  Kim S, Kim SA, Han J, Kim IS. Kim S, et al. Int J Mol Sci. 2021 Nov 29;22(23):12916. doi: 10.3390/ijms222312916. Int J Mol Sci. 2021. PMID: 34884721 Free PMC article. Review.
• DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia.
  Golla U, Ehudin MA, Annageldiyev C, Zeng Z, Bastihalli Tukaramrao D, Tarren A, Date AA, Elcheva I, Berg A, Amin S, Loughran TP Jr, Kester M, Desai D, Dovat S, Claxton D, Sharma A. Golla U, et al. Cancers (Basel). 2021 Sep 29;13(19):4889. doi: 10.3390/cancers13194889. Cancers (Basel). 2021. PMID: 34638385 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information